At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,651 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without Transarterial Chemoembolization as First-line Treatment for Advanced Hepatocellular Carcinoma With Vascular Invasions
In Brief
An observational study for Hepatocellular Carcinoma (HCC). Completed, enrolled 2,651 participants across 1 site.
Detailed Summary
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma with vascular invasions
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma (HCC)
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedMar 2025
Primary CompletionMar 2025
Study CompletionSep 2025
TodayJul 2026
First PostedMar 18, 2025
Enrollment StartJun 1, 2018
Primary CompletionMar 30, 2025
Study CompletionSep 30, 2025
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 1.3 years ago